Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: liraglutide Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

GLP_1 RA Ultrasound Study

NCT06581120
View directory record Official record
Conditions
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
Interventions
Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
Drug · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 30, 2026, 4:46 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

NCT01722227
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

NCT02963922
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Liraglutide 3.0 mg, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Concord, California • Fresno, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

NCT01473953
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Healthy
Interventions
liraglutide-depot, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 30, 2026, 4:46 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.

NCT03500484
View directory record Official record
Conditions
Obesity, Childhood, Neural Development
Interventions
Liraglutide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

NCT02870231
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 30, 2026, 4:46 AM EDT
Recruiting Phase 2 Interventional

Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy

NCT06903923
View directory record Official record
Conditions
Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification, Bone Density, Obesity
Interventions
GLP-1 receptor agonist, Lifestyle intervention
Drug · Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Sep 30, 2026, 4:46 AM EDT
Terminated Phase 4 Interventional

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598
View directory record Official record
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615
View directory record Official record
Conditions
OSA
Interventions
AD109
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Monroe, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 30, 2026, 4:46 AM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 30, 2026, 4:46 AM EDT
Not listed Phase 4 Interventional

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

NCT02344186
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Sep 30, 2026, 4:46 AM EDT
Withdrawn Phase 4 Interventional

Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

NCT02198209
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

NCT01511198
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
39
States / cities
Vestavia Hills, Alabama • Tucson, Arizona • Carlisle, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 30, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01516476
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6807952, liraglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

Liraglutide Hospital Discharge Trial

NCT01919489
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide + OADs, Glargine + OADs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

NCT01388361
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin aspart, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
48
States / cities
Concord, California • La Jolla, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 30, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

NCT04883346
View directory record Official record
Conditions
Obesity, Status Post Sleeve Gastrectomy
Interventions
Liraglutide
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 20 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 30, 2026, 4:46 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 30, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 30, 2026, 4:46 AM EDT